BioSpace News Archive

Drug Development

RenovoRx and Parexel Biotech Reach Key Milestone in Clinical Trial for Locally-Advanced Pancreatic CancerTIGeR-PaC Phase III trial reaches first patient in Europe, with overall enrollment exceeding 20 percent worldwide

RenovoRx, Inc., an innovator in targeted cancer therapy, and Parexel Biotech, a division of Parexel, one of the world’s leading global clinical research organizations focused on accelerating the development and delivery of innovative new therapies to improve world health, announced the TIGeR-PaC Phase III clinical trial of Trans-Arterial Micro-Perfusion has reached its first patient enrolled in Europe.

January 13, 2020
·
3 min read
Business

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site Activation and Patient Enrollment

January 13, 2020
·
7 min read
Genetown

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

In a presentation to investors on Wednesday, January 15, 2020, at 10:30 a.m. PST at the 38th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. President and CEO Cynthia Collins will discuss the Company’s progress on developing in vivo and engineered cell medicines and building the leading genomic medicine company.

January 13, 2020
·
7 min read
Business

Livongo and Dexcom Partner to Integrate Dexcom’s G6 Continuous Glucose Monitoring System into Livongo’s Applied Health Signals Platform

Dexcom CGM to become a core part of Livongo’s solution for delivering personalized health insights and improved clinical outcomes to people with Diabetes

January 13, 2020
·
4 min read
Genetown

Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference

Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M.1, on track for market leadership in 2020.

January 13, 2020
·
9 min read
Drug Development

Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that it has received Institutional Review Board approval from Stanford University to commence the VIITAL™ study, the Company’s pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

January 13, 2020
·
6 min read
Business

MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia

The Muscular Dystrophy Association and AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s ataxia, announced the award of MDA Venture Philanthropy funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a gene-replacement therapy for the disease.

January 13, 2020
·
5 min read
Deals

Cigna Ventures Invests in Two Breakthrough Companies to Accelerate Digital Health Innovation and Connect Customers to Care Anywhere, Anytime

New partnerships further Cigna’s strategy to connect customers to care everywhere and meet them where they are - at home, at work, on the go

January 13, 2020
·
6 min read
Business

Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific

Kap-Seok Yang, CEO of Macrogen, announced on January 13 that the company has signed a strategic License and Supply Agreement with Thermo Fisher Scientific.

January 13, 2020
·
2 min read
Genetown

University of Chicago Offers Mammosphere from Life Image to Support WISDOM Study Participants, Improve Breast Health Research

Top academic medical center to leverage leading breast health data tool to improve breast screening protocols for groundbreaking study

January 13, 2020
·
4 min read